BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 21129072)

  • 1. T-cell prolymphocytic leukemia: A rare disease in an elderly female.
    Madaris L
    J Am Acad Nurse Pract; 2010 Dec; 22(12):648-53. PubMed ID: 21129072
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epstein-barr virus-positive diffuse large B-cell lymphoma during therapy with alemtuzumab for T-cell prolymphocytic leukemia.
    Sohani AR; Ferry JA; Chang PS; Abramson JS
    J Clin Oncol; 2010 Feb; 28(5):e69-72. PubMed ID: 19917859
    [No Abstract]   [Full Text] [Related]  

  • 3. A case report of T cell prolymphocytic leukemia and Kaposi sarcoma and a review of T cell prolymphocytic leukemia.
    Paul RN; Alizadeh L; Ajayi OI; Karpurapu H; Ganesan C; Taddesse-Heath L; Aggarwal A
    Acta Haematol; 2012; 127(4):235-43. PubMed ID: 22517037
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current treatment options in prolymphocytic leukemia.
    Robak T; Robak P
    Med Sci Monit; 2007 Apr; 13(4):RA69-80. PubMed ID: 17392661
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Generalized leukaemia cutis from a small cell variant of T-cell prolymphocytic leukaemia presenting with exfoliative dermatitis.
    Jeong KH; Lew BL; Sim WY
    Acta Derm Venereol; 2009; 89(5):509-12. PubMed ID: 19734979
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Guillain-Barré syndrome after use of alemtuzumab (Campath) in a patient with T-cell prolymphocytic leukemia: a case report and review of the literature.
    Abbi KK; Rizvi SM; Sivik J; Thyagarajan S; Loughran T; Drabick JJ
    Leuk Res; 2010 Jul; 34(7):e154-6. PubMed ID: 20362332
    [No Abstract]   [Full Text] [Related]  

  • 7. T-cell prolymphocytic leukemia.
    Dearden CE
    Clin Lymphoma Myeloma; 2009; 9 Suppl 3():S239-43. PubMed ID: 19778847
    [TBL] [Abstract][Full Text] [Related]  

  • 8. T-cell prolymphocytic leukemia: update and focus on alemtuzumab (Campath-1H).
    Cao TM; Coutre SE
    Hematology; 2003 Feb; 8(1):1-6. PubMed ID: 12623420
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Conjunctival involvement with T-cell prolymphocytic leukemia: report of a case and review of the literature.
    Lee SS; Robinson MR; Morris JC; Mirtsching BC; Shen D; Chan CC
    Surv Ophthalmol; 2004; 49(5):525-36. PubMed ID: 15325197
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Infiltration of the thyroid gland by T-cell prolymphocytic leukemia.
    Fujiwara K; Fukuhara T; Kitano H; Okazaki T
    Thyroid; 2014 Aug; 24(8):1314-8. PubMed ID: 24762052
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of Alemtuzumab Therapy and Route of Administration in T-Prolymphocytic Leukemia: A Single-Center Experience.
    Damlaj M; Sulai NH; Oliveira JL; Ketterling RP; Hashmi S; Witzig T; Nowakowski G; Call TG; Shanafelt TD; Ding W; Hogan WJ; Litzow MR; Patnaik MM
    Clin Lymphoma Myeloma Leuk; 2015 Nov; 15(11):699-704. PubMed ID: 26422251
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rhodococcus equi infection after alemtuzumab therapy for T-cell prolymphocytic leukemia.
    Meeuse JJ; Sprenger HG; van Assen S; Leduc D; Daenen SM; Arends JP; van der Werf TS
    Emerg Infect Dis; 2007 Dec; 13(12):1942-3. PubMed ID: 18258054
    [TBL] [Abstract][Full Text] [Related]  

  • 13. T-cell prolymphocytic leukaemia (T-PLL): a rare disease with a grave prognosis.
    Vivekanandarajah A; Atallah JP; Gupta S
    BMJ Case Rep; 2013 May; 2013():. PubMed ID: 23645660
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Successful treatment of T-cell prolymphocytic leukemia (T-PLL) with fludarabine monophosphate].
    Maeda A; Iwai K; Ishibashi T
    Rinsho Ketsueki; 2009 Aug; 50(8):658-62. PubMed ID: 19915381
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alemtuzumab.
    Ravandi F; O'Brien S
    Expert Rev Anticancer Ther; 2005 Feb; 5(1):39-51. PubMed ID: 15757437
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stem cell transplantation after alemtuzumab in T-cell prolymphocytic leukaemia results in longer survival than after alemtuzumab alone: a multicentre retrospective study.
    Krishnan B; Else M; Tjonnfjord GE; Cazin B; Carney D; Carter J; Ketterer N; Catovsky D; Ethell M; Matutes E; Dearden CE
    Br J Haematol; 2010 Jun; 149(6):907-10. PubMed ID: 20201944
    [No Abstract]   [Full Text] [Related]  

  • 17. T-cell prolymphocytic leukemia.
    Khot A; Dearden C
    Expert Rev Anticancer Ther; 2009 Mar; 9(3):365-71. PubMed ID: 19275513
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [T-cell prolymphocytic leukemia: potential diagnostic pitfalls].
    Dessart P; Lemaire P; Le Dû K; Sandrini J; Prophette B; Maillard H
    Ann Dermatol Venereol; 2014 Dec; 141(12):777-81. PubMed ID: 25433931
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TCL-1-positive hematogones in a patient with T-cell prolymphocytic leukemia after therapy.
    Hu Z; Li S; Medeiros LJ; Sun T
    Hum Pathol; 2017 Jul; 65():175-179. PubMed ID: 28232160
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alemtuzumab in the treatment of chronic lymphocytic lymphoma.
    Boyd K; Dearden CE
    Expert Rev Anticancer Ther; 2008 Apr; 8(4):525-33. PubMed ID: 18402519
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.